Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Research article

Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival

Authors: J. Ripoll, M. Ramos, J. Montaño, J. Pons, A. Ameijide, P. Franch

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Information about survival by stage in bladder cancer is scarce, as well as about survival of non-invasive bladder cancer. The aims of this study are: 1) to find out the distribution of bladder cancer by stage; 2) to determine cancer-specific survival by stage of bladder cancer; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers.

Methods

Incident bladder cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. Inclusion criteria: cases with code C67 according to the ICD-O 3rd edition with any behaviour and any histology, except lymphomas and small cell carcinomas. Cases identified exclusively through the death certificate were excluded. We collected the following data: sex; age; date and method of diagnosis; histology according to the ICD-O 3rd edition; T, N, M and stage at the time of diagnosis; and date of follow-up or death. End point of follow-up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Cases with benign or indeterminate behaviour were excluded for the survival analysis. Actuarial and Kaplan-Meier methods and Cox regression models were used for survival analysis.

Results

One thousand nine hundred fourteen cases were identified. 14% were women and 65.4% were 65 years or older. 3.9% had no stage (benign or undetermined behaviour) and 11.5% had unknown stage. After MI, 37.5% were in stage Ta (non-invasive papillary carcinoma), 3.2% in stage Tis (carcinoma in situ), 34.3% in stage I, 11.7% in Stage II, 4.3% in stage III, and 9.0% in stage IV. Survival was 76% at 5 years. Survival by stage: 98% at stage Ta, 90% at stage Tis, 85% at stage I, 45% at stage II, 35% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage, but not sex, were associated with survival.

Conclusion

Bladder cancer survival vary greatly with stage, among both non-invasive and invasive cases. The percentage of non-invasive cancers is high. Stage, age, and histology are associated to survival.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. https://doi.org/10.1002/ijc.29210.CrossRefPubMed

Galceran J, Carulla M, Almela F, Chico M, Marcos AI, Marcos-Gragera R, et al. Oral communication presented at: XLIV Annual Meeting of the Groupe pour l’Epidémiologie et l’Enregistrement du Cancer dans les Pays de Langue Latine; 2019, 29–31 May. Lisbon; 2019.

Mortalidad de cáncer en España. Instituto de Salud Carlos III. Available at: http://ariadna.cne.isciii.es/MapaP/ [checked the 08 Sept 2019].

Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, et al. Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5. Eur J Cancer. 2015;51:2217–30.CrossRefPubMed

Kamat AM, Hahn NM, Efstathiou JA, Lerner SSP, Malmström PU, Choi W, et al. Bladder cancer. Lancet. 2016;388(10061):2796–810. https://doi.org/10.1016/S0140-6736(16)30512-8.CrossRefPubMed

Al-Husseini MJ, Kunbaz A, Saad AM, Santos JV, Salahia S, Iqbal M, et al. Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis. BMC Cancer. 2019;19(1):46. https://doi.org/10.1186/s12885-019-5267-3.CrossRefPubMedPubMedCentral

Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013;37(3):219–25. https://doi.org/10.1016/j.canep.2013.02.002.CrossRefPubMed

Andreassen BK, Aagnes B, Gislefoss R, Andreassen M, Wahlqvist R. Incidence and survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014. BMC Cancer. 2016;16(1):799. https://doi.org/10.1186/s12885-016-2832-x.CrossRefPubMedPubMedCentral

Andreassen BK, Grimsrud TK, Haug ES. Bladder cancer survival: women better off in the long run. Eur J Cancer. 2018;95:52–8. https://doi.org/10.1016/j.ejca.2018.03.001.CrossRefPubMed

10.

Wallerand H, Bernhard J-C, Culine S, Ballanger P, Robert G, Reiter RE, et al. Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urol Oncol. 2011;29(1):4–11. https://doi.org/10.1016/j.urolonc.2009.07.025.CrossRefPubMed

11.

Pedersen AB, Mikkelsen EM, Cronin-Fenton D, Kristensen N, Pham TM, Pedersen L, et al. Missing data and Mul-tiple imputation in clinical epidemiological research. Clin Epidemiol. 2017;9:157–66. https://doi.org/10.2147/CLEP.S129785.CrossRefPubMedPubMedCentral

12.

Eisemann N, Waldmann A, Katalinic A. Imputation of missing values oftumour stage in population-based cancer registration. BMC Med Res Methodol. 2011;11:129.26.CrossRef

13.

Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology (ICD-O), 1st rev., 3rd. Geneva: World Health Organization; 2013. Available at: https://apps.who.int/iris/bitstreZam/handle/10665/96612/9789241548496%20eng.pdf;jsessionid=7B2E052FBC84832B13B32AC8B483E069?sequence=1 [checked the 05 July 2019].

14.

Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Oxford: Wiley; 2011.

15.

Parrya MG, Sujenthiranb A, Cowlinga TE, Charmanb S, Nossitera J, Aggarwala A, et al. Imputation of missing prostate cancer stage in English cancer registry data based on clinical assumptions. Cancer Epidemiol. 2019;58:44–51. https://doi.org/10.1016/j.canep.2018.11.003.CrossRef

16.

White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377–99. https://doi.org/10.1002/sim.4067.CrossRefPubMed

17.

Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987. https://doi.org/10.1002/9780470316696.CrossRef

18.

Ramos M, Montano J, Esteva M, et al. Colorectal cancer survival by stage of cases diagnosed in Mallorca, Spain, between 2006 and 2011 and factors associated with survival. Cancer Epidemiol. 2016;41:63–70. https://doi.org/10.1016/j.canep.2016.01.001.CrossRefPubMed

19.

Ederer F, Heise H. The effect of eliminating deaths from cáncer on general population survival rates. Methodological Note No, 11, End Results Evaluation Section. National Cancer Institute; 1959.

20.

EUROCARE web. Available at: https://w3.iss.it/site/EU5Results/forms/SA0007.aspx [checked the 23 Dec 2019].

21.

Damgaard K, Bray F, Moller B. A comparison of relative and cause-specific survival by cancer site, age and time since diagnosis. Int J Cancer. 2013;135:196–203.

22.

Makkar N, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations. Cancer Med. 2018;7(9):4773–80. https://doi.org/10.1002/cam4.1706.CrossRefPubMedPubMedCentral

23.

Chen Q, Li L, Wang G, Hu J, Sun T, Fu B. Do histological variants in urothelial carcinoma of the bladder portend poor prognosis? A systematic review and meta-analysis. Oncotarget. 2017;8(29):48263–71. https://doi.org/10.18632/oncotarget.17593.CrossRefPubMedPubMedCentral

24.

Bilski K, Zapała Ł, Skrzypczyk MA, Oszczudłowski M, Dobruch J. Review on gender differences in non-muscle invasive bladder cancer. Transl Androl Urol. 2018;8:12–20.CrossRef

25.

Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology and outcomes. Eur Urol. 2016;69(2):300–10. https://doi.org/10.1016/j.eururo.2015.08.037.CrossRefPubMed

26.

Wolff I, Brookman-May S, May M. Sex difference in presentation and outcomes of bladder cancer: biological reality of statistical fluke? Curr Opin Urol. 2015;25(5):418–26. https://doi.org/10.1097/MOU.0000000000000198.CrossRefPubMed

27.

Eloranta S, Adolfsson J, Lambert PC, Stattin P, Akre O, Andersson TML, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control. 2013;24(3):505–15. https://doi.org/10.1007/s10552-012-0141-5.CrossRefPubMed

28.

Andreassen BK, Myklebust TA, Haug ES. Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway. Scand J Urol. 2017;51(1):38–43.

29.

Poletajew S, Biernacki R, Buraczynski P, Chojnacki J, Czarniecki S, Gajewska D, et al. Stage of bladder cancer in Central Europe – polish perspective. Neoplasma. 2016;63(04):642–7. https://doi.org/10.4149/neo_2016_420.CrossRefPubMed

Title: Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival
Authors: J. Ripoll
M. Ramos
J. Montaño
J. Pons
A. Ameijide
P. Franch
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08418-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Conspicuity of malignant pleural mesothelioma in contrast enhanced MDCT – arterial phase or late phase?

The Will Rogers phenomenon, breast cancer and race

Resilience and its associated factors in head and neck cancer patients in Pakistan: an analytical cross-sectional study

Validation of grading of non-invasive urothelial carcinoma by digital pathology for routine diagnosis

Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome

Incidence, clinical risk and prognostic factors for liver metastasis in patients with cervical cancer: a population-based retrospective study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer